Several synthetic FXR agonists have been developed and are in clinical trials, such as obeticholic acid (OCA) for the treatment of primary sclerosing cholangitis and Cilofexor for non-alcoholic steatohepatitis (NASH) [7,8,9,10]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.